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AUTHORS' SUMMARY
H eterotrimeric guanine nucleotide-binding protein (G protein) coupled receptors (GPCRs) are a remarkably versatile family of transmembrane signaling molecules that present extraordinary therapeutic potential as drug targets for a wide spectrum of diseases (1) . A better understanding of GPCR structure will help to elucidate the mechanism by which they transmit signals across the plasma membrane and will facilitate the development of more effective and selective drugs. Rhodopsin, the lightsensitive photoreceptor found in the mammalian eye, is also a GPCR, and its structure has been determined. Obtaining high-resolution structures of GPCRs other than rhodopsin, however, has been challenging because of their low natural abundance and inherent structural flexibility and instability (2) . As a result, the application of structure-based drug discovery to GPCRs has largely been limited to the use of rhodopsin-based homology models. We have applied targeted protein engineering to make other GPCRs better candidates for crystallographic structure analysis, using the human b 2 -adrenergic receptor as an initial candidate. The b 2 -adrenergic receptor binds the hormones adrenaline and noradrenaline to regulate cardiovascular and pulmonary function. Our results show that targeted protein engineering can be used to obtain highresolution structures of GPCRs.
Efforts to crystallize the wild-type (WT) b 2 -adrenergic receptor have been unsuccessful. We identified the third intracellular loop (ICL3) as a possible contributor to the difficulties in crystallization. This region interacts with signaling molecules such as G proteins. ICL3 is poorly structured and contributes to the relatively unrestricted movement of the transmembrane helices, which leads to the receptor's conformational heterogeneity and crystallization problems. Truncation of ICL3 could reduce the movement of the helices, but this would also reduce the polar surface area that is important for forming crystal-lattice contacts. Thus, we replaced ICL3 with T4 lysozyme (T4L), a well-folded protein that adds a polar surface and simultaneously restricts the movement of transmembrane helices linked by the inserted sequence (see the figure) . The resulting fusion protein could be efficiently expressed in insect cells and purified. It also retained ligand binding affinities near those of the WT receptor and could undergo conformational changes upon agonist binding.
The engineered protein formed crystals in two different lipid environments: bicelles and lipidic cubic phase. Crystals grown in lipidic cubic phase yielded a 2.4 Å x-ray diffraction data set from which we determined the structure by molecular replacement, using T4 lysozyme and a polyalanine model of the transmembrane regions of rhodopsin as search models [see (3) ].
One must be concerned that the structural modifications that facilitated crystal formation could produce a highresolution structure that does not reflect the WT b 2 -adrenergic receptor. The fusion protein exhibited slightly elevated agonist binding affinities; however, antagonist binding affinities were normal, and only minor differences were observed when the b 2 -adrenergic receptor-T4L structure was compared to a 3.4 Å structure of the WT b 2 -adrenergic receptor crystallized in complex with an antibody fragment (4) . Therefore, with the exception of ICL3, the structure of b 2 -adrenergic receptor-T4L probably reflects that of the native receptor.
Although we know the structure of the GPCR rhodopsin, our structure of the b 2 -adrenergic receptor now provides a high-resolution view of a GPCR that binds diffusible hormones and neurotransmitters and should facilitate structurebased drug development. Moreover, it can help to reveal how structural changes are propagated from the agonist binding site to the G protein-coupling domains. The methods that we used to obtain these crystals will probably be applicable to other GPCRs, allowing the determination of their structures and increasing our understanding of transmembrane signal transduction and drug discovery for this important class of molecules.
Nevertheless, a full understanding of the structural basis of GPCR activation will require a high-resolution structure of a complex between a receptor with an agonist bound and its G protein, as well as methods to assess the dynamics of their interaction that cannot be captured by the static snapshots provided by x-ray crystallography. Future nuclear magnetic resonance (NMR) experiments, which capture some of the dynamics, could identify key GPCR residues: those critical for binding different classes of ligands, propagating conformational changes, and forming allosteric interaction sites for signaling partners such as G proteins and arrestins. When interpreted in the context of high-resolution crystal structures, NMR and other dynamics experiments will lead to a better understanding of GPCR signaling and how such signaling can be manipulated with small molecules to therapeutic effect.
FULL-LENGTH ARTICLE
The b 2 -adrenergic receptor (b 2 AR) is a well-studied prototype for heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) that respond to diffusible hormones and neurotransmitters. To overcome the structural flexibility of the b 2 AR and to facilitate its crystallization, we engineered a b 2 AR fusion protein in which T4 lysozyme (T4L) replaces most of the third intracellular loop of the GPCR ("b 2 AR-T4L") and showed that this protein retains near-native pharmacologic properties. Analysis of adrenergic receptor ligand-binding mutants within the context of the reported high-resolution structure of b 2 AR-T4L provides insights into inverse-agonist binding and the structural changes required to accommodate catecholamine agonists. Amino acids known to regulate receptor function are linked through packing interactions and a network of hydrogen bonds, suggesting a conformational pathway from the ligand-binding pocket to regions that interact with G proteins.
T he adrenergic receptors make up a class of heterotrimeric guanine nucleotidebinding protein (G protein)-coupled receptors (GPCRs) that play a central role in mediating the effects of catecholamine hormones. In contrast to rhodopsin, which is expressed at very high levels in photoreceptor cells and has the ligand retinal covalently bound (1), other GPCRs such as the b 2 -adrenergic receptor (b 2 AR) generally express at low levels, bind diffusible ligands, and exhibit greater functional and structural plasticity (2). The b 2 AR was the first non-rhodopsin GPCR to be cloned and has been one of the most extensively studied members of this large receptor family.
To obtain high-resolution structural information on the b 2 AR, we increased its proteolytic stability and crystallizability by eliminating the C-terminal tail and replacing most of the third intracellular loop (ICL3) with the protein T4 lysozyme (T4L). The optimized b 2 AR-T4L protein was crystallized in lipidic cubic phase, as described in the companion paper by Cherezov et al. (3) , and the resulting 2.4 Å resolution crystal structure reveals the interface between the receptor and the ligand carazolol, a partial inverse agonist (4) . Analysis of mutagenesis data in light of the structure clarifies the roles of different amino acids in inverseagonist binding and implies that rearrangement of the binding pocket accompanies agonist binding. In addition, the structure reveals how mutations known to cause constitutive activity or uncoupling of agonist binding and G protein activation are distributed between the ligand-binding pocket and the cytoplasmic surface of the protein, such that changes in side chains due to interaction with the ligand can be transmitted through the structure to the site of G protein interaction.
b 2 AR-T4L: A crystallizable GPCR fusion protein. The conformational complexity that makes GPCRs versatile signaling molecules may contribute to the difficulty of crystallizing these proteins (2) . Despite substantial efforts, we were unable to grow diffraction-quality crystals from purified, homogeneous wild-type (WT) b 2 AR. This was probably due to conformational variability of the flexible ICL3 and C terminus, as well as the relatively small polar surface available for crystal contacts. Fluorescence resonance energy transfer experiments show that the C-terminal portion of the b 2 AR is in an extended conformation (5), a property that may be important for the role of this region in interacting with signaling and scaffold proteins, but one that would probably interfere with crystal-lattice formation. ICL3, which links the cytoplasmic ends of helices V and VI, is functionally important both for the specificity of receptor-G protein interactions and for G protein activation. In the b 2 AR, this domain is susceptible to proteolysis; however, proteolytic cleavage does not lead to dissociation of the transmembrane segments linked by the ICL3. In fact, b 2 AR helices I to V and helices VI and VII behave as independent folding domains that can be expressed on separate plasmids and assemble to form a functional "split" receptor (6) . Therefore, we speculated that ICL3 links two domains with a relatively dynamic interface, which could be important for function but may also contribute to greater instability.
Because the majority of membrane protein crystals form through contacts of the nonmembranous portions of the molecule, we sought to improve the chances of b 2 AR crystallization by replacing ICL3 with a well-structured, soluble domain that might aid in the formation of lattice contacts. The initial criteria for choosing the inserted soluble protein were that the N and C termini would approximate the predicted distance between the cytoplasmic ends of helix V and helix VI and that the protein would crystallize under a variety of conditions. T4L is a small, stable protein that fulfills these criteria (7) . The N and C termini of WT T4L are 10.7 Å apart in Protein Data Bank (PDB) structure 2LZM (8), compared with a distance of 15.9 Å between the carbonyl carbon of residue 228 5 .63 (9) and the amide nitrogen of residue 241 6.24 in the high-resolution structure of rhodopsin (PDB 1U19) (10 of the b 2 AR were replaced by residues 2 to 164 of T4L (construct "E3" in Fig. 1A ). In addition, the receptor was truncated at position 365, which aligns approximately with the position of the rhodopsin C terminus. Although these modifications resulted in a receptor that was expressed efficiently in Sf 9 cells, further optimization was carried out to reduce the length of the junction between the receptor and the T4L termini (13) . Several candidate constructs are illustrated in Fig.  1A , and selected immunofluorescence images of transfected, permeabilized human embryonic kidney (HEK) 293 cells are shown in Fig. 1B .
Relative to the initial construct, we could remove three residues from the cytoplasmic end of helix V, three from the C-terminal end of T4L, and three from the N terminus of helix VI, all without losing substantial cell-surface expression. The final construct used for crystallization trials (b 2 AR-T4L) has residues 231 5.70 to 262 6.24 of the b 2 AR replaced by amino acids 2 to 161 of T4L (D1 in Fig. 1A ). Similar reduction of flexibility through minimization of linker length has been important in previous crystallization studies on soluble fusion proteins (14) .
Functional properties of b 2 AR-T4L. We mea- Fig. 2A, fig. S1 , and table S1). The results show that b 2 AR-T4L has WT affinity for the antagonist [ 3 H]DHA and the inverse agonist ICI-118,551, whereas the affinity for both agonists (e.g., isoproterenol, epinephrine, formoterol) and a partial agonist (salbutamol) is two-tothreefold higher relative to WT b 2 AR. Higher agonist binding affinity is a property associated with constitutively active mutants (CAMs) of GPCRs. CAMs of the b 2 AR also exhibit elevated basal, agonist-independent activation of the stimulatory G protein for adenylyl cyclase (Gs) and typically have lower expression levels and reduced stability (15, 16) . b 2 AR-T4L exhibits binding properties of a CAM, but it expresses at levels exceeding 1 mg/liter of Sf 9 cell culture, is more resistant to trypsin proteolysis than the WT b 2 AR ( fig. S2 ), and retains binding activity in detergent at 37°C, as well as the WT receptor ( fig. S3 ).
b 2 AR-T4L did not couple to Gs, as expected, because of the replacement of ICL3 by T4L. To assess whether the fused protein alters receptor function at the level of its ability to undergo conformational changes, we used a covalently attached fluorescent probe as a reporter for ligand-induced structural changes. Fluorophores attached at Cys265 6.27 , at the cytoplasmic end of helix VI, detect agonist-induced conformational changes that correlate with the efficacy of the agonist toward G protein activation (17) (18) (19) (20) . Detergent-solubilized b 2 AR365 (WT receptor truncated at 365) and b 2 AR-T4L were each labeled with monobromobimane, which has been used previously to monitor conformational changes of the b 2 AR (21). The addition of the agonist isoproterenol to purified b 2 AR365 induces a decrease in fluorescence intensity and a shift in the wavelength at maximum intensity (l max ) for the attached bimane probe ( Fig. 2B and table S2 ). These changes in intensity and l max are consistent with an agonist-induced increase in polarity around bimane. A smaller change is observed with the partial agonist salbutamol, whereas the inverse agonist ICI-118,551 had little effect. For the b 2 AR-T4L, there are subtle differences in the baseline spectrum of the bimane-labeled fusion protein, as might be expected if the environment around Cys265 6.27 is altered by T4L. However, the full agonist isoproterenol induces a qualitatively similar decrease in intensity and rightward shift in l max . Thus, the presence of the fused T4L does not prevent agonist-induced conformational changes. The partial agonist salbutamol induced larger responses in b 2 AR-T4L than were observed in WT b 2 AR, and there was a small increase in fluorescence in response to the inverse agonist ICI-118,551. These properties are observed in CAMs (15, 22) and are consistent with the higher affinities for agonists and partial agonists exhibited by b 2 AR-T4L. Therefore, we conclude that the T4L fusion induces a partial constitutively active phenotype in the b 2 AR, probably caused by changes at the cytoplasmic ends of helices V and VI.
Comparison between b 2 AR-T4L and b 2 ARFab structures. The b 2 AR-T4L fusion strategy is validated by a comparison of its structure to that of WT b 2 AR complexed with a Fab that recognizes a three-dimensional epitope consisting of the N-and C-terminal ends of ICL3, determined at an anisotropic resolution of 3.4 Å/3.7 Å (23). Figure 3A illustrates the similarity between the fusion and antibody complex approaches to b 2 AR crystallization, in that both strategies rely on attachment (covalent or noncovalent, respectively) of a soluble protein partner between helices V and VI. A major difference between the two structures is that the extracellular loops and the carazolol ligand could not be modeled in the b 2 AR-Fab complex, whereas these regions are resolved in the structure of b 2 AR-T4L. Nonetheless, it is clear that the T4L insertion does not substantially alter the receptor. Superposition of the two structures ( fig. S4 ) illustrates that the transmembrane helices of the receptor components are very similar (root mean square deviation = 0.8 Å for 154 common modeled transmembrane Ca positions versus 2.3 Å between b 2 AR-T4L and the 154 equivalent residues in rhodopsin), especially when the modest resolution of the Fab complex is taken into account.
There is one major difference between the Fab-complex and chimeric-receptor structures that can be attributed to the presence of T4L. The cytoplasmic end of helix VI is pulled outward as a result of the fusion to the C terminus of T4L, which alters the packing of Phe264 6.26 at the end of helix VI (Fig. 3B) . In the Fabcomplex b 2 AR, interactions between Phe264 6.26 and residues in helix V, helix VI, and ICL2 may be important in maintaining the b 2 AR in the basal state. The loss of these packing interactions in b 2 AR-T4L could contribute to the higher agonist binding affinity characteristic of a CAM.
An unexpected difference between the structure of rhodopsin and the b 2 AR-T4L involves the sequence E/DRY (24) found at the cytoplasmic end of helix III in 71% of class A GPCRs. In rhodopsin, Glu134
3.49 and Arg135 3.50 form a network of hydrogen bond and ionic interactions with Glu247
6.30 at the cytoplasmic end of helix VI. These interactions have been referred to as an "ionic lock" that stabilizes the inactive state of rhodopsin and other class A members (25) . However, the arrangement of the homologous residues is considerably different in b 2 AR-T4L: Arg131 3.50 interacts primarily with Asp130
3.49 , and the distance between helix III and helix VI is greater than in rhodopsin (Fig. 3C) . This difference might be explained by the interaction between Glu268
6.30 and Arg8 of T4L; however, the arrangement of Asp130 3.49 and Arg131 3.50 and the distance between helix III and helix VI is very similar to that observed in the b 2 AR-Fab structure. Although the presence of an antibody or T4L at the ICL3 region could potentially affect the arrangement of these residues, the fact that similar ionic-lock structures were obtained using two different approaches suggests that a broken ionic lock may be a genuine feature of the carazolol-bound state of the receptor. Ligand binding to the b 2 AR. The b 2 AR-T4L fusion protein was purified and crystallized in complex with the inverse agonist carazolol. Carazolol stabilizes the b 2 AR against extremes of pH and temperature, perhaps related to its unusually high binding affinity (equilibrium dissociation constant K d < 0.1 nM) and slow dissociation kinetics (half-time t 1/2~3 0 hours) ( fig. S5 ).
The interactions between carazolol and b 2 AR-T4L are depicted schematically in Fig. 4 . The carbazole ring system is oriented roughly perpendicular to the plane of the membrane, and the alkylamine chain (atoms 15 to 22 in the model) is nearly parallel to the heterocycle (Fig. 5, A and B) . Carazolol was modeled into the electron density (3) as the (S)-(-) isomer because of the higher affinity of this enantiomer, despite the fact that a racemic mixture of the ligand was used in crystallization. Asp113 (Figs. 4 and 5,  A and B) . Asp113 3.32 was one of the first b 2 AR residues shown to be important for ligand binding; the D113N mutation causes a complete loss of detectable affinity for antagonists (26) and a decrease in the potency of agonists toward cellbased G protein activation by over four orders of magnitude (27) . Likewise, mutations of Asn312 7.39 perturb b 2 AR binding to agonists and antagonists: Changes to nonpolar amino acids (Ala or Phe) reduce affinities to undetectable levels, whereas retention of a polar functionality (Thr or Gln) gives partial affinity (28) . On the opposite end of the ligand near helix V, N 7 of the carbazole heterocycle forms a hydrogen bond with the side-chain hydroxyl of Ser203 5.42 . Mutations of Ser203 5.42 specifically decrease b 2 AR affinity toward catecholamine agonists and aryloxyalkylamine ligands with nitrogen-containing heterocycles such as pindolol (29) and, by implication, carazolol. Thus, the polar interactions between carazolol and the receptor observed in the crystal structure agree with the known biochemical data. The contribution of Tyr316 7.43 to antagonist and , and Phe290 6.52 are red, and all other residues are gray. (D) Model of (-)-isoproterenol (magenta sticks) in the ligand binding pocket observed in the crystal structure. A model of the agonist with optimal bond lengths and angles was obtained from the PRODRG server (44) , and the dihedral angles were adjusted to the values observed in the homologous atoms of bound carazolol (16 to 22 in Fig. 4) . The one remaining unaccounted dihedral in (-)-isoproterenol was adjusted in order to place the catechol ring in the same plane as the C 16 -C 15 -O 14 plane in carazolol. Residues known to specifically interact with agonists are shown as green sticks. agonist affinity remains to be tested; this residue is conserved as Tyr in all sequenced adrenergic receptor genes (12) . Figure 5C shows the tight packing between carazolol and surrounding amino acids that buries 790 Å 2 of surface area from solvent; specific contacts are depicted schematically in Fig. 4 . Notable among the hydrophobic residues contacting carazolol are Val114 3.33 , Phe290 6.52 , and Phe193 5.32 . The side chain of Val114 3.33 from helix III makes multiple contacts with the C 8 -to-C 13 ring of the carbazole heterocycle, and Phe290 6.52 from helix VI forms an edge-to-face aromatic interaction with the same ring. As a result, these two amino acids form a hydrophobic "sandwich" with the portion of the aryl moiety that is common to many adrenergic antagonists. The mutation of Val114 3.33 to Ala was shown to decrease b 2 AR affinity toward the antagonist alprenolol by one order of magnitude, as well as to lower affinity for the agonist epinephrine 300-fold (30). Phe193 5.32 is different from other carazolol contact residues in that it is located on the second extracellular loop, in the path of hormone accessibility to the binding pocket. This amino acid contributes more buried surface area than any other residue to the interface between b 2 AR-T4L and carazolol (table S3) . Therefore, Phe193 5.32 is likely to contribute substantially to the energy of b 2 AR-carazolol complex formation, and the position of this residue on the extracellular side of the binding site may allow it to act as a gate that contributes to the unusually slow dissociation of the ligand (fig. S5) .
Analysis of the binding pocket provides insights into the structural basis for pharmacologic selectivity between the b 2 AR and closely related adrenergic receptors such as the b 1 AR. The affinities of these two receptors for certain ligands, such as ICI-118,551, betaxolol, and RO363 (31), differ by up to 100-fold. Curiously, all of the amino acids in the carazolol binding pocket are conserved between the b 1 AR and b 2 AR [ fig. S6 in (13) ]. The majority of the 94 amino acid differences between the b 1 AR and b 2 AR are found in the cytoplasmic and extracellular loops. Whereas residues that differ in the transmembrane segments generally face the lipid bilayer, eight residues lie at the interface between helices and may influence helix packing. The structural basis for pharmacologic differences between b 1 AR and b 2 AR must, therefore, arise from amino acid differences in the entrance to the binding pocket or subtle differences in the packing of helices. Evidence for the latter comes from chimeric-receptor studies (32) in which successive exchange of helices between b 1 AR and b 2 ARs led to a gradual change in affinity for the b 2 AR selective ICI-118,551 and the b 1 AR selective betaxolol.
As discussed above, b 2 AR-T4L shows CAMlike properties with respect to agonist binding affinities, suggesting that the unliganded b 2 AR-T4L may exist in a more active conformation than the WT b 2 AR. Nevertheless, as shown in Fig. 2B , b 2 AR-T4L can be stabilized in an inactive conformation by an inverse agonist. Because b 2 AR-T4L was crystallized with bound carazolol, a partial inverse agonist, the structure most likely represents an inactive state. This is consistent with the similarity of the b 2 AR-T4L and b 2 AR-Fab5 carazolol-bound structures. To assess whether conformational changes are required to accommodate catecholamines, a model 6.34 are shown as yellow spheres or dot surfaces. A vertical cross section through the structure illustrates that these surrounding residues connect the CAMs on helices III and VI with the UCMs on helix VII through packing interactions. (B) In both b 2 AR-T4L (blue) and rhodopsin (purple), a network of ordered water molecules is found at the interface between the transmembrane helices at their cytoplasmic ends. (C) Network of hydrogen bonding interactions between water molecules and b 2 AR-T4L residues (side chains shown as blue sticks), notably three UCMs on helix VII (orange) and one on helix II (yellow). In (B) and (C), only Ballesteros-Weinstein numbers (9) are used to identify amino acids. of isoproterenol was placed in the binding site such that common atoms (16 to 22 in Fig. 4) were superimposed onto the analogous carazolol coordinates in the crystal structure (Fig. 5D) 5.46 to the para-hydroxyl of the catechol ring, respectively (33) . In our model, the catechol hydroxyls of isoproterenol face the appropriate Ser residues on helix V, but the distances are too long for hydrogen bonding (6.8 Å from the meta-hydroxyl oxygen to the side-chain oxygen of Ser204 5.43 and 4.8 Å from the para-hydroxyl oxygen to the side-chain oxygen of Ser207 5.46 ). In addition, Asn293
6.55 and Tyr308 7.35 , two residues expected to form selective interactions with agonists based on the literature (34, 35) , are too distant to form productive polar or hydrophobic contacts with the modeled isoproteronol molecule. These observations suggest that agonist binding requires changes in the binding site relative to the carazololbound structure, unless common structural components of agonists and inverse agonists bind in a considerably different manner.
Structural insights into b 2 AR activation. Biophysical studies provide evidence that conformational changes associated with activation of the b 2 AR are similar to those observed for rhodopsin (2, 18, 21, 36 ). Yet the highly efficient process of light activation of rhodopsin through the cis-trans isomerization of covalently bound retinal is very different from activation of the b 2 AR and other GPCRs by diffusible hormones and neurotransmitters (2). Despite representing a static picture of the inverse agonist-bound state, the crystal structure of b 2 AR-T4L may still provide clues as to how agonist binding is translated into structural changes in the cytoplasmic domains of receptor. Agonist binding occurs at the extracellular ends of helices III, IV, V, and VII, and G protein activation is mediated by the cytoplasmic ends. Whereas the structure is open at the extracellular face to form the ligand binding pocket, the helices are more closely packed in the intracellular half of the receptor. This close packing implies that isolated rigid-body movement of any of these helices is unlikely and that conformational changes can be accomplished only by rearrangement of the side chains forming the network of interactions between the helices. Biophysical studies show that structurally different agonists stabilize distinct active states (17, 20) , suggesting that different ligands could stabilize different combinations of side-chain rearrangements. Analysis of mutations that affect b 2 AR function provides insights into structural rearrangements that are likely to occur during receptor activation. Figure 6A illustrates the location of amino acids for which mutations lead to elevated basal, agonistindependent activity (CAMs), as well as amino acids for which mutations impair agonist activation [uncoupling mutations (UCMs)]. Residues for which CAMs have been described are likely to be involved in interactions that maintain the receptor in the inactive conformation. These amino acids are centrally located on helices III and VI. In contrast, positions in which UCMs have been observed are likely to form intramolecular interactions that stabilize the active state. A cluster of UCMs is found at the cytoplasmic end of helix VII. Neither CAMs nor UCMs are directly involved in agonist binding. Although the CAMs and UCMs are not directly connected in sequence, it is evident from the structure that they are linked through packing interactions, so that movements in one will probably affect the packing of others. For example, Fig. 6A (right panel) shows all amino acids with atoms within 4 Å of the two centrally located CAMs, Leu124 3.43 (37) and Leu272 6.34 (38) . Several amino acids that pack against these CAMs also interact with one or more UCMs. Trp286 6.48 lies at the base of the binding pocket. It has been proposed that agonist binding leads to a change in the rotameric state of Trp286 6.48 , with subsequent changes in the angle of the helical kink formed by Pro288 6.50 (39) . It is likely that an agonist-induced change in the rotameric state of Trp286 6.48 will be linked to changes in side chains of CAMs and UCMs through packing interactions and propagated to the cytoplasmic ends of the helices and the associated intracellular loops that interact with G proteins and other signaling molecules.
In the structures of both rhodopsin and the b 2 AR, a cluster of water molecules lies near the most highly conserved class A GPCR residues (Fig. 6B) . It has been proposed that these water molecules may play a role in the structural changes involved in receptor activation (40) . Figure 6C shows the network of potential hydrogen bonding interactions that link Trp286 6.48 with conserved amino acids extending to the cytoplasmic ends of helices. UCMs have been identified for four amino acids linked by this network: Asp79 2.50 , Asn318 7.45 , Asn322 7.49 , and Y326 7.53 (41) . This relatively loose-packed, water filled region is probably important in allowing conformational transitions, as there will be fewer steric restraints to side-chain repacking. Future structures of the agonist-bound state of the b 2 AR will help to clarify the precise rearrangements that accompany activation of the receptor.
Although crystallization of b 2 AR-T4L in the presence of other ligands remains an exciting prospect, future efforts to obtain structures of the catecholamine-bound receptor will be challenging because of the relatively low affinity of these compounds in the absence of G protein and their chemical lability. Moreover, biophysical studies indicate that agonist binding and activation is a multistep process involving distinct conformational intermediates (2, 17, (19) (20) (21) 42) , which produces structural heterogeneity even at saturating concentrations of agonist. It is therefore possible that structural elucidation of the active state of the b 2 AR will be possible only through crystallization of the complex between agonist, b 2 AR, and Gs. proteins has also been reported by Privé and co-workers for lactose permease. Tables S1 to S3 
